. Illumina, Inc. (NASDAQ:ILMN) is one of the last week's best-performing stocks. Illumina rallied by 23.4 percent ...

Genomics company Illumina (NASDAQ:ILMN) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

Illumina continues to focus on transforming human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related ...

Illumina’s revenue was flat for the third quarter as the sequencing giant continues to deal with headwinds from a China sales ...

Discover key Q3 2025 earnings insights for Illumina, including raised outlook, NovaSeq X growth, and margin expansion.

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street ...

Investing.com -- Illumina Inc (NASDAQ:ILMN) reported better-than-expected third-quarter results on Thursday, with earnings surpassing analyst estimates and the company raising its full-year outlook, ...

Eli Lilly partners with Nvidia to build the pharma industry’s most powerful AI supercomputer, aiming to speed up drug ...

KUALA LUMPUR, Oct 28 (Bernama) -- The US-ASEAN Business Council (USABC), in partnership with the ASEAN Committee on Science, ...